Cognitive Enhancers in Dementia: When to Start, What to Expect, and When to Stop
Type: Keynote Therapeutic: Geriatrics,Neurology,Psychiatry,Mental Health
Thursday May 10 1:50pm to 2:50pm Location: Lecture Hall 1 Credits: 1 Mainpro+
This lecture will review the indications for treatment of dementia with cognitive enhancers (cholinesterase inhibitors and memantine) based on clinical practice guidelines. The modest improvements in cognition, function and behavior will be emphasized, along with potential adverse events. Emerging evidence on when to discontinue (“deprescribe”) will be also be reviewed.
Review the indications for cognitive enhancers in dementia.
Be able to initiate and monitor cognitive enhancer therapy for dementia.
Review when, and how to deprescribe cognitive enhancers in dementia.
Nathan Herrmann MD, FRCPC
Dr Herrmann is the Richard Lewar Chair in Geriatric Psychiatry at Sunnybrook Health Sciences Centre and the University of Toronto. He is a Professor of Psychiatry in the Faculty of Medicine at the University of Toronto. He is Head of the Division of Geriatric Psychiatry at Sunnybrook Health Sciences Centre and was Head of the Division of Geriatric Psychiatry at the University of Toronto from 1994-2005. At Sunnybrook, he is co-director of the Clinical Neuropharmacology Laboratory and a scientist in the Hurvitz Brain Sciences Research Program and the Center for Stroke Recovery.